Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Klinik For Fodterapi hos Statsautoriserede fodterapeuter Anders Jensen & Lizette Falk ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   5.5% 5.3% 5.3% 4.0% 3.9% 6.7% 9.4% 9.0%   Credit score (0-100)   42 42 40 50 49 36 26 27   Credit rating   BBB BBB BBB BBB BBB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   1,378 1,124 1,284 1,329 1,263 1,296 1,296 1,296   Gross profit   967 757 938 940 883 815 0.0 0.0   EBITDA   295 243 353 366 348 231 0.0 0.0   EBIT   192 140 250 263 294 181 0.0 0.0   Pre-tax profit (PTP)   126.8 81.4 213.9 244.2 273.5 174.3 0.0 0.0   Net earnings   138.6 73.0 166.8 190.0 213.0 135.9 0.0 0.0   Pre-tax profit without non-rec. items   127 81.4 214 244 274 174 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Tangible assets total   167 113 58.9 5.0 0.0 0.0 0.0 0.0   Shareholders equity total   8.5 81.5 248 438 651 787 737 737   Interest-bearing liabilities   363 959 673 438 211 3.1 0.0 0.0   Balance sheet total (assets)   1,258 1,111 1,015 1,026 1,010 928 737 737   Net Debt   338 949 660 319 35.8 -121 -109 -109     See the entire balance sheet 1000.0 Volume  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   1,378 1,124 1,284 1,329 1,263 1,296 1,296 1,296   Net sales growth   -55.3% -18.4% 14.2% 3.5% -5.0% 2.6% 0.0% 0.0%   Gross profit   967 757 938 940 883 815 0.0 0.0   Gross profit growth   0.9% -21.7% 23.9% 0.2% -6.0% -7.7% -100.0% 0.0%   Employees   2 0 0 0 0 0 0 0   Employee growth %   0.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,258 1,111 1,015 1,026 1,010 928 737 737   Balance sheet change%   -1.3% -11.7% -8.6% 1.1% -1.6% -8.1% -20.6% 0.0%   Added value   294.9 242.8 353.0 366.0 397.5 230.7 0.0 0.0   Added value %   21.4% 21.6% 27.5% 27.5% 31.5% 17.8% 0.0% 0.0%   Investments   -185 -206 -206 -206 -108 -99 0 0   Net sales trend   -1.0 -2.0 1.0 2.0 -1.0 1.0 0.0 0.0   EBIT trend   1.0 2.0 3.0 4.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A EBITDA %   21.4% 21.6% 27.5% 27.5% 27.6% 17.8% 0.0% 0.0%   EBIT %   13.9% 12.4% 19.5% 19.8% 23.3% 14.0% 0.0% 0.0%   EBIT to gross profit (%)   19.8% 18.4% 26.6% 28.0% 33.3% 22.3% 0.0% 0.0%   Net Earnings %   10.1% 6.5% 13.0% 14.3% 16.9% 10.5% 0.0% 0.0%   Profit before depreciation and extraordinary items %   17.5% 15.7% 21.0% 22.1% 21.2% 14.3% 0.0% 0.0%   Pre tax profit less extraordinaries %   9.2% 7.2% 16.7% 18.4% 21.7% 13.5% 0.0% 0.0%   ROA %   15.0% 12.6% 24.9% 27.1% 29.9% 19.4% 0.0% 0.0%   ROI %   15.8% 13.3% 27.0% 30.8% 35.0% 22.8% 0.0% 0.0%   ROE %   21.6% 162.3% 101.2% 55.3% 39.1% 18.9% 0.0% 0.0%   1000.0 Solidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Equity ratio %   0.7% 7.3% 24.5% 42.7% 64.5% 84.8% 100.0% 100.0%   Relative indebtedness %   90.7% 91.6% 59.7% 44.2% 28.4% 10.9% 0.0% 0.0%   Relative net indebtedness %   88.9% 90.7% 58.7% 35.3% 14.6% 1.3% -8.4% -8.4%   Net int. bear. debt to EBITDA, %   114.7% 390.8% 186.9% 87.3% 10.3% -52.5% 0.0% 0.0%   Gearing %   4,288.3% 1,176.7% 271.0% 100.0% 32.3% 0.4% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   21.4% 10.2% 6.2% 5.9% 9.6% 13.1% 0.0% 0.0%   1000.0 Liquidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Quick Ratio   0.2 0.1 0.1 0.4 0.6 1.2 0.0 0.0   Current Ratio   0.4 0.4 0.4 0.7 0.8 1.9 0.0 0.0   Cash and cash equivalent   24.9 9.9 13.2 118.9 174.8 124.2 0.0 0.0   1000.0 Capital use efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Trade debtors turnover (days)   14.6 8.4 1.8 9.6 7.1 12.6 0.0 0.0   Trade creditors turnover (days)   14.3 15.6 2.8 22.9 14.7 22.9 0.0 0.0   Current assets / Net sales %   13.7% 12.8% 11.7% 19.8% 23.9% 20.8% 8.4% 8.4%   Net working capital   -237.1 -263.4 -207.5 -139.4 -57.5 127.7 0.0 0.0   Net working capital %   -17.2% -23.4% -16.2% -10.5% -4.5% 9.9% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales / employee   689 0 0 0 0 0 0 0   Added value / employee   147 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   147 0 0 0 0 0 0 0   EBIT / employee   96 0 0 0 0 0 0 0   Net earnings / employee   69 0 0 0 0 0 0 0